Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional) | RFA DA 21 031

Opportunity Information: Apply for RFA DA 21 031

The funding opportunity titled "Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)" (Funding Opportunity Number RFA-DA-21-031) is a National Institutes of Health (NIH) small business grant initiative designed to accelerate the development of practical, commercial-ready digital health products that can reduce substance use risk and improve outcomes by addressing social determinants of health. Rather than focusing only on the biological or clinical aspects of addiction, this announcement centers on the real-world social and environmental conditions that shape vulnerability to drug use and recovery trajectories, including but not limited to opioid-related harms. The overall goal is to support research and development efforts that translate into scalable tools that can be deployed in communities, health systems, and support settings where people affected by substance use disorders live and seek help.

This announcement uses the SBIR phased mechanism (R41/R42), which is specifically aimed at small businesses developing technologies with a clear path toward commercialization. In practice, Phase I (R41) generally supports early-stage feasibility, proof-of-concept, prototype development, and initial testing, while Phase II (R42) supports more advanced research and development, refinement, and stronger evidence-building toward real-world use and market readiness. The phrase "Clinical Trial Optional" signals that applicants may propose projects that include a clinical trial, but they are not required to do so. That flexibility allows companies to pursue a range of evidence-generation approaches, from user-centered design and feasibility pilots to larger effectiveness studies, depending on the maturity of the product and the scientific questions being addressed.

The key emphasis is on digital technologies that can positively influence social determinants of health in the context of substance use disorders. Social determinants of health typically include factors like housing stability, employment and income, education, access to transportation, food security, exposure to violence, social support, discrimination, and access to health and social services. Under this opportunity, the digital product should not merely track these factors, but aim to measurably improve them or reduce their negative impacts in ways that are relevant to substance use prevention, treatment engagement, harm reduction, relapse prevention, or long-term recovery. That could mean building tools that help people navigate services, connect with community resources, coordinate care, improve communication and trust between patients and providers, reduce barriers to attending treatment, or strengthen protective social connections. The announcement is oriented toward interventions that address upstream drivers of risk, recognizing that unstable living conditions, limited access to resources, and structural barriers can directly affect drug use patterns and the ability to start and sustain recovery.

Because the opportunity is focused on commercializable products, applications are expected to reflect a product-development mindset alongside scientific rigor. Competitive proposals typically articulate a clear unmet need, define the intended users and use settings, describe the digital solution in concrete terms, and outline a development plan that includes usability, implementation considerations, and an evidence strategy appropriate for the stage of the technology. While the source text does not list specific technical requirements, the "digital health-based products" framing generally encompasses software and mobile applications, telehealth or remote support platforms, digital screening and referral tools, digital therapeutics, and other technology-enabled service models that can be integrated into real-world workflows. The commercialization focus also implies that applicants should be thinking about adoption pathways, potential customers or purchasers (such as providers, payers, public health entities, or employers), regulatory and privacy considerations when applicable, and how the product could be sustained beyond the grant period.

Eligibility is limited to small businesses, consistent with NIH SBIR requirements. Importantly, non-domestic (non-U.S.) entities are not eligible to apply, and non-domestic components of U.S. organizations are also not eligible. However, the announcement notes that "foreign components" may be allowed as defined by the NIH Grants Policy Statement. In NIH terms, that typically means a U.S.-based applicant organization may, under certain circumstances and with appropriate justification and approvals, include a discrete portion of the project to be performed outside the United States when it offers a unique resource or expertise not readily available domestically. Even when allowed, such foreign components are not the same as a foreign applicant, and they must align with NIH policy and be well-justified as necessary for the project.

Administratively, this is a discretionary grant opportunity under NIH, associated with CFDA number 93.279. The opportunity was created on December 22, 2020, and the original closing date listed is February 26, 2021. The provided source excerpt does not specify an award ceiling or the number of expected awards, which means those details would normally be confirmed in the full announcement on NIH/Grants.gov or the NIH Guide notice. The administering agency is the National Institutes of Health, and given the RFA-DA prefix, it is associated with NIH's drug abuse portfolio, aligning with the focus on populations affected by the use of drugs including opioids.

In short, this grant is aimed at U.S. small businesses building digital tools that do more than provide clinical content; they are expected to confront the social and environmental realities that drive substance use risk and complicate recovery. The NIH is effectively signaling that meaningful progress on substance use disorders requires solutions that can operate in everyday contexts, reduce structural barriers, and connect people to resources and supports, and that digital technologies are a promising way to deliver those improvements at scale with a viable commercialization pathway.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.279.
• This funding opportunity was created on 2020-12-22.
• Applicants must submit their applications by 2021-02-26. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA DA 21 031

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: